Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acasti Pharma, Inc. - Common Stock (NQ:ACST)

3.370 UNCHANGED
Last Price Updated: 3:44 PM EDT, Oct 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Acasti Pharma, Inc. - Common Stock

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Acasti Pharma Reports Third Quarter 2023 Operational Results
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - January 17, 2023) - The Stock Day Podcast welcomed Acasti Pharma, Inc. (NASDAQ: ACST), a late-stage... 
Via Newsfile
Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Pharma Reports Second Quarter 2023 Operational Results
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Pharma to Present at Q4 Investor Summit
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022
Call to be held on Monday, November 14th at 1:00 PM Eastern Time 
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Pharma Inc. (NASDAQ:ACST) (TSX.V:ACST) Featured in Coverage of Investor Summit Group’s Q4 Event
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Acasti Announces Court Dismissal of Stockholder Litigation
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - September 21, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"),... 
Via Newsfile
Exposures Product Safety
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - July 7, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"),... 
Via Newsfile
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public... 
From MicroCap Rodeo
Via AccessWire
Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th
LAVAL, QC / ACCESSWIRE / May 12, 2022 / Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST)(TSXV:ACST), today announced that Jan D'Alvise, Chief Executive Officer, has been invited to present... 
From Acasti Pharma Inc.
Via AccessWire
Acasti Pharma Inc. CEO, Jan D'Alvise, Is Featured on The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - February 22, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"),... 
Via Newsfile
ACASTI PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Acasti Pharma Inc. - ACST
From Kahn Swick & Foti, LLC
Via Business Wire
Acasti Pharma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Acasti Pharma Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ACST
From Halper Sadeh LLP
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.